AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie's Acquisition of
Pharmacyclics
NORTH CHICAGO, Ill., May 22, 2015 -- AbbVie (NYSE: ABBV) announced today that the waiting period
under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for AbbVie's purchase of Pharmacyclics,
Inc. has expired today.
The expiration satisfies the exchange offer condition with respect to the approvals and clearances
required under antitrust laws. Assuming that the other customary exchange offer conditions are satisfied,
including a minimum tender of at least a majority of outstanding Pharmacyclics shares, it is expected that
the exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics will expire
today at 5:00 p.m., New York City time, without any further extension.
About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from
Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique
approach to innovation to develop and market advanced therapies that address some of the world's most
complex and serious diseases. AbbVie employs more than 26,000 people worldwide and markets
medicines in more than 170 countries. For further information on the company and its people, portfolio
and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our
Facebook or LinkedIn page.
Forward-Looking Statements
This news release contains forward-looking statements that involve risks and uncertainties. Such forwardlooking statements include the expected structure and timetable for the transaction between AbbVie and
Pharmacyclics. The statements in this release are based upon current expectations and are subject to
certain risks and uncertainties that could cause actual results to differ materially from those described in
the forward-looking statements. These risks and uncertainties include risks and uncertainties related to,
among other things: failure to satisfy the conditions to consummate the offer and the merger; the
occurrence of any event, change or other circumstances that could give rise to the termination of the
merger agreement; the failure of the offer or the merger to close for any other reason; the amount of the
costs, fees, expenses and charges related to the offer and the merger; general economic and business
conditions, global economic growth and activity; industry conditions; changes in laws or regulation; and
other factors beyond the companies' control as well as the risk factors and other cautionary statements
described in AbbVie's and Pharmacyclics' filings with the SEC. Please refer to the Risk Factors section of
AbbVie's Registration Statement on Form S-4, as filed on March 23, 2015 for a further list and description
of additional business risks, uncertainties, and other factors that may affect these statements. All
subsequent written and oral forward-looking statements attributable to AbbVie or Pharmacyclics or any
person acting on their behalf are qualified by the cautionary statements in this section.
Important Additional Information
This press release does not constitute an offer to purchase, or a solicitation of an offer to sell, shares of
common stock of Pharmacyclics, nor is it a substitute for the Registration Statement on Form S-4 and
tender offer materials that AbbVie filed with the Securities and Exchange Commission ("SEC") on March
23, 2015, each as amended.
Investors and security holders of Pharmacyclics are urged to read the tender offer statement on Schedule
TO, filed on March 23, 2015 (as amended, the "Schedule TO"), the Registration Statement on Form S-4,
as filed on March 23, 2015 (as amended, the "Registration Statement"), and the
solicitation/recommendation statement filed by Pharmacyclics on Schedule 14D-9, filed on March 23,
2015 (as amended, the "Schedule 14D-9"). The tender offer materials (including an offer to purchase,
letter of transmittal and related tender offer documents), the Registration Statement and the Schedule

14D-9 contain important information which should be read carefully before any decisions are made with
respect to the Offer.
In addition to the Schedule TO, the Schedule 14D-9 and the Registration Statement described above,
AbbVie and Pharmacyclics file annual, quarterly and current reports, proxy statements and other
information with the SEC. The Schedule TO, the Schedule 14D-9, the Registration Statement and any
other relevant materials, and any other documents filed with the SEC by AbbVie or Pharmacyclics, are
available without charge at the SEC's website at www.sec.gov, or from the companies' websites, at
www.abbvieinvestor.com and http://www.pharmacyclics.com, respectively.
Free copies of the exchange offer materials (including the Registration Statement and the Schedule TO)
are also available on AbbVie's website at www.abbvieinvestor.com and copies of the Schedule 14D-9 are
available on Pharmacyclics' website http://www.pharmacyclics.com. Copies of the exchange offer
materials (including the Registration Statement and the Schedule TO) may also be obtained free of
charge from Georgeson Inc., the information agent for the exchange offer, by calling, toll-free, (888) 6801528 or emailing PCYC@georgeson.com.
SOURCE AbbVie Inc.
CONTACT: Media: Adelle Infante, (847) 938-8745, Investors: Liz Shea, (847) 935-2211

